MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer’s disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
Metrics to compare | 4586 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship4586PeersSector | |
---|---|---|---|---|
P/E Ratio | −5.3x | 10.5x | −0.6x | |
PEG Ratio | 0.04 | 0.06 | 0.00 | |
Price/Book | 3.9x | 1.0x | 2.6x | |
Price / LTM Sales | 164.0x | 1.4x | 3.3x | |
Upside (Analyst Target) | - | 8.2% | 38.7% | |
Fair Value Upside | Unlock | 2.7% | 5.1% | Unlock |